Process Development of the Pyrazinecarboxamide Component of Gilteritinib, a FLT3 Inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Process Development of the Pyrazinecarboxamide Component of Gilteritinib, a FLT3 Inhibitor

Published:2024-05-24 Issue:6 Volume:28 Page:2317-2324
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Sugimori Toshiyuki¹^ORCID,Akiba Takahiro²

Affiliation:

1. Chemical & Biological Technology Labs., CMC Development, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan

2. PJ Acceleration, CMC Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan

Funder

Astellas Pharma

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00119

Reference26 articles.

1. Shimada, I.; Kurosawa, K.; Matsuya, T.; Iikubo, K.; Kondoh, Y.; Kamikawa, A.; Tomiyama, H.; Iwai, Y. Preparation of diamino heterocycle-carboxamide compounds as EML4-ALK fusion protein kinase inhibitors. World Patent WO2010128659, 2010.

2. Eguchi, T.; Mori, M.; Yamaki, Y. Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient. World Patent WO2015119122, 2015.

3. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

4. Press release by Astellas Pharma Inc. https://www.astellas.com/en/system/files/news/2018-12/181211_1_Eg.pdf (accessed 2024–02–13).

5. Press release by Astellas Pharma Inc. https://www.astellas.com/en/about/main-products (accessed 2024–03–05).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP